SynthesisEuropean journal of clinical pharmacology2019
Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis.
Synthesis in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis.Schizophrenia bulletin · 2025Pooled it
- Deciphering the genetic landscape of obesity: a data-driven approach to identifying plausible causal genes and therapeutic targets.Journal of human genetics · 2023Pooled it
- Short-term neonatal outcomes in women with gestational diabetes treated using metformin versus insulin: a systematic review and meta-analysis of randomized controlled trials.Acta diabetologica · 2023Pooled it
- Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression.Frontiers in endocrinology · 2022Pooled it
- Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis.BMC public health · 2021Pooled it
- Metformin as adjuvant therapy in obese knee osteoarthritis patients.Inflammopharmacology · 2024Trial
- Dosing Strategies for High-Alert Medications in Obese Pediatric Patients: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Vitamin D Adequacy Conditions the Prolactin-Suppressive Effect of Metformin in Men Receiving Prolactin-Elevating Medications.Nutrients · 2026Article
- Rethinking about Metformin: Promising Potentials.Korean journal of family medicine · 2024Article
- Vitamin D Status Determines the Impact of Metformin on Gonadotropin Levels in Postmenopausal Women.Journal of clinical medicine · 2023Article
- Article
- Pleiotropic Effects of Metformin in Osteoarthritis.Life (Basel, Switzerland) · 2023Review
- Antiobesity effect ofFood & nutrition research · 2023Article
- Psychiatric manifestations of Kleefstra syndrome: a case report.Frontiers in psychiatry · 2023Article
- Weight-centric treatment of type 2 diabetes mellitus.Obesity pillars · 2022Review
- Metformin and vitamin D modulate adipose-derived stem cell differentiation towards the beige phenotype.Adipocyte · 2022Article
- Targeting skeletal muscle mitochondrial health in obesity.Clinical science (London, England : 1979) · 2022Review
- Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2022Article
- Article
- Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review.Clinical pharmacology : advances and applications · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOur aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta-analysis and to identify the most suitable dosage and intervention period for using metformin in adolescents and adults.
methodsWe searched databases for studies published by April 2018. A total of 34 trials (44 analyses) involving 8461 participants and 16 intervention arms were eligible. The study was registered with PROSPERO International prospective register of systematic reviews (CRD42017081053).
resultsMetformin was found to significantly decrease body mass index percentile (BMI) and had a tendency to decrease BMI (kg/m
conclusionWhen considering the efficacy of interventions for losing weight, metformin offers clear advantages for overweight and obese populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.